Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 9.9% Higher - Still a Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) traded up 9.9% during trading on Monday . The company traded as high as $34.53 and last traded at $35.16. 269,403 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 923,454 shares. The stock had previously closed at $31.98.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Alliance Global Partners reissued a "buy" rating on shares of Tonix Pharmaceuticals in a research note on Tuesday, June 3rd. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Finally, Noble Financial restated an "outperform" rating and issued a $70.00 target price on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.

Tonix Pharmaceuticals Stock Performance

The firm has a market capitalization of $267.67 million, a PE ratio of -0.01 and a beta of 2.09. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company's fifty day moving average price is $25.07 and its two-hundred day moving average price is $23.65.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The firm had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.55 million. As a group, equities analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.

Insider Activity

In other news, CEO Seth Lederman acquired 4,000 shares of the company's stock in a transaction dated Thursday, May 15th. The shares were bought at an average price of $21.55 per share, for a total transaction of $86,200.00. Following the completion of the purchase, the chief executive officer now directly owns 4,005 shares of the company's stock, valued at approximately $86,307.75. This trade represents a 80,000.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.03% of the company's stock.

Institutional Trading of Tonix Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Commonwealth Equity Services LLC acquired a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth approximately $40,000. Two Sigma Investments LP acquired a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth approximately $66,000. Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth approximately $162,000. IFP Advisors Inc acquired a new stake in shares of Tonix Pharmaceuticals during the first quarter worth approximately $179,000. Finally, Rhumbline Advisers acquired a new stake in shares of Tonix Pharmaceuticals during the first quarter worth approximately $244,000. Hedge funds and other institutional investors own 82.26% of the company's stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.